Effect of Acarbose on Vascular Disease in Patients with Abnormal Glucose Tolerance

Hanefeld, Markolf; Schäper, Frank; Koehler, Carsta

doi:10.1007/s10557-008-6091-1

Cited by 36 publications

(33 citation statements)

References 54 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Improvement in postprandial hyperglycemia following treatment with an ␣-glucosidase inhibitor in patients with type 2 diabetes has been shown to have beneficial effects for cardiovascular disease (6,(8)(9)(10). Moreover, acarbose, an ␣-glucosidase inhibitor, delays progression of impaired glucose tolerance to diabetes and cardiovascular disease (7,30).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Extracts of Common Buckwheat Bran Prevent Sucrose Digestion

Hosaka

Nii²,

Tomotake

et al. 2011

J Nutr Sci Vitaminol

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…Inhibitors of ␣ -glucosidase, which prevent the hydrolyzation of carbohydrates in the gastrointestinal tract, are commonly used to improve postprandial hyperglycemia in patients with type 2 diabetes and some have shown beneficial effects on both cardiovascular disease and progression to diabetes (6)(7)(8)(9)(10).…”

mentioning

confidence: 99%

Extracts of Common Buckwheat Bran Prevent Sucrose Digestion

Hosaka

Nii²,

Tomotake

et al. 2011

J Nutr Sci Vitaminol

View full text Add to dashboard Cite

“…Due to it being scarcely digestible and generally having no detectable toxicity (Wehmeier and Piepersberg 2004), it is currently used in the therapy of type II diabetes, in which it can better control the blood sugar contents of patients after meals (Hanefeld et al 2008).…”

Section: Introductionmentioning

confidence: 99%

An effective and simplified scale-up strategy for acarbose fermentation based on the carbon source control

Wie

Huang

et al. 2011

World J Microbiol Biotechnol

View full text Add to dashboard Cite

The scale-up strategy for acarbose fermentation by Actinoplanes sp. A56 was explored in this paper. The results obtained in shake-flask cultivation demonstrated that the ratio of maltose and glucose had significant effects on the biosynthesis of acarbose, and the feeding medium containing 3:1 (mass ratio) of maltose and glucose was favorable for acarbose production. Then the correlation of the carbon source concentration with acarbose production was further investigated in 100-l fermenter, and the results showed that 7.5-8.0 g of total sugar/100 ml and 4.0-4.5 g of reducing sugar/100 ml were optimal for acarbose production. Based on the results in 100-l fermenter, an effective and simplified scale-up strategy was successfully established for acarbose fermentation in a 30-m(3) fermenter, by using total sugar and reducing sugar as the scale-up parameter. As a result, 4,327 mg of acarbose/l was obtained at 168 h of fermentation.

show abstract

“…-Glucosidase inhibitors have been reported to treat postprandial hyperglycemia and hypertension, as well as to suppress the incidence of cardiovascular events 13 . In a previous study we showed that acarbose, an -glucosidase inhibitor, suppresses plasma levels of the remnant fraction in the fasting state 14 .…”

Section: Originalmentioning

confidence: 99%

Effect of Miglitol, an α-Glucosidase Inhibitor, on Postprandial Glucose and Lipid Metabolism in Patients with Type 2 Diabetes

Kaneko

Kuboki

Hiroi

et al. 2011

Showa Univ J Med Sci

View full text Add to dashboard Cite

: Objective : The effects of miglitol on postprandial glucose and lipid metabolism were investigated in patients with type 2 diabetes mellitus T2DM treated with diet alone. Subjects and Methods : A meal tolerance test MTT was performed in 26 diabetic patients before and 2 weeks after 150 mg / day miglitol treatment, with the second MTT performed in patients after they had taken a dose of 50 mg miglitol. Results : Miglitol treatment decreased postprandial blood glucose and serum insulin levels 30 and 60 min after meal loading, but there was no change in blood glucose levels at 120 min. In addition, there were no significant decreases in the area under the curve AUC of blood glucose and serum insulin levels. However, the AUC of postprandial serum triglycerides and incremental triglycerides decreased signi cantly, as did the AUC of postprandial incremental remnant-like particle cholesterol. There were no signi cant changes in total cholesterol, high-density lipoprotein-cholesterol and low-density lipoprotein-cholesterol. Conclusions : Miglitol treatment improves postprandial hyperlipidemia, as well as postprandial hyperglycemia, in patients with T2DM. In T2DM patients treated with -glucosidase inhibitors alone, measuring blood glucose levels 120 min after a meal may not be the best way to monitor postprandial glucose metabolism.

show abstract

Effect of Acarbose on Vascular Disease in Patients with Abnormal Glucose Tolerance

Abstract: Thus results so far available prove that acarbose is an effective and safe drug to treat abnormal glucose tolerance. They suggest that acarbose can help to control a broad spectrum of CV risk factors and may prevent CV disease.

Cited by 36 publications

References 54 publications

Extracts of Common Buckwheat Bran Prevent Sucrose Digestion

Extracts of Common Buckwheat Bran Prevent Sucrose Digestion

An effective and simplified scale-up strategy for acarbose fermentation based on the carbon source control

Effect of Miglitol, an α-Glucosidase Inhibitor, on Postprandial Glucose and Lipid Metabolism in Patients with Type 2 Diabetes

Contact Info

Product

Resources

About